Caplin Point Q2 FY27 consolidated revenue Rs 629.84 cr; PAT Rs 182.35 cr

Caplin Point Q2 FY27 consolidated revenue Rs 629.84 cr; PAT Rs 182.35 cr

For Q2 FY27, Caplin Point Laboratories reported consolidated revenue from operations of Rs 629.84 cr and PAT of Rs 182.35 cr, up from Rs 534.04 cr and Rs 160.23 cr in Q2 FY26.

Caplin Point Laboratories Ltd
Caplin Point Laboratories LtdReviewed and published by · How we report
3 min read
caplin pointq2 fy27earningspharmaresults
ShareWhatsAppXLinkedIn

Key takeaways

  • Revenue from operations was Rs 629.84 cr vs Rs 534.04 cr in Q2 FY26.
  • Total income rose to Rs 663.13 cr from Rs 564.41 cr a year earlier.
  • Total expenses increased to Rs 430.33 cr from Rs 363.43 cr in Q2 FY26.
  • Profit before tax was Rs 232.83 cr vs Rs 201.00 cr in the year-ago quarter.
  • PAT for Q2 FY27 was Rs 182.35 cr vs Rs 160.23 cr, with basic EPS at Rs 23.44 vs Rs 20.32.

Q2 FY27 · consolidated

MetricSep 2026Sep 2025Change
RevenueRs 629.84 crRs 534.04 cr+18.0%
PATRs 182.35 crRs 160.23 cr+13.8%
EPSRs 23.44Rs 20.32+15.3%

As reported in the filing. Figures are transcribed, not computed.

Caplin Point Laboratories Ltd's next results reach Pro the minute they're filed.Try Pro free for 14 days

What the numbers show

  • Net margin was 28.95% of revenue, down 105 bps from 30.00%.
  • Purchases of stock-in-trade accounted for Rs 28.63 cr of the Rs 66.90 cr rise in total expenses (42%).
  • Purchases of stock-in-trade took 23.9% of revenue, against 22.8% a year earlier.

• Revenue from operations (Q2 FY27, consolidated): Rs 629.84 cr vs Rs 534.04 cr in Q2 FY26
• Other income: Rs 33.29 cr vs Rs 30.37 cr
• Total income: Rs 663.13 cr vs Rs 564.41 cr
• Cost of materials consumed: Rs 106.15 cr vs Rs 92.34 cr
• Purchase of traded goods: Rs 150.31 cr vs Rs 121.68 cr
• Changes in inventories of finished goods, stock in trade and work in progress: Rs (17.79) cr vs Rs (3.72) cr
• Employee benefits expense: Rs 57.59 cr vs Rs 48.03 cr
• Finance costs: Rs 0.22 cr vs Rs 0.16 cr
• Depreciation & amortisation expense: Rs 23.49 cr vs Rs 18.40 cr
• Other expenses: Rs 110.36 cr vs Rs 86.54 cr
• Total expenses: Rs 430.33 cr vs Rs 363.43 cr
• Profit before share of profit in associate, exceptional items and tax: Rs 232.80 cr vs Rs 200.98 cr
• Share of profit/(loss) in associate: Rs 0.03 cr vs Rs 0.02 cr
• Exceptional items: - vs -
• Profit before tax: Rs 232.83 cr vs Rs 201.00 cr
• Current tax: Rs 54.78 cr vs Rs 36.53 cr
• Deferred tax: Rs (4.30) cr vs Rs 4.24 cr
• Total tax expenses: Rs 50.48 cr vs Rs 40.77 cr
• Net profit for the period (PAT): Rs 182.35 cr vs Rs 160.23 cr
• Other comprehensive income – items that will not be re-classified to profit or loss (remeasurements of defined benefit plan): Rs 1.06 cr vs Rs 1.34 cr
• Income tax relating to these items: Rs (0.27) cr vs Rs (0.34) cr
• Other comprehensive income – items that will be re-classified to profit or loss (exchange difference in translating the financial statements of foreign operations): Rs 24.36 cr vs Rs 46.54 cr
• Total comprehensive income for the period: Rs 207.50 cr vs Rs 207.77 cr
• Profit attributable to owners of the company: Rs 178.10 cr vs Rs 154.45 cr
• Profit attributable to non-controlling interests: Rs 4.25 cr vs Rs 5.78 cr
• Total comprehensive income attributable to owners of the company: Rs 203.25 cr vs Rs 201.99 cr
• Total comprehensive income attributable to non-controlling interests: Rs 4.25 cr vs Rs 5.78 cr
• Paid up equity share capital (face value Rs 2/- each): Rs 15.20 cr vs Rs 15.20 cr
• Other equity excluding non-controlling interest (full year prior only): Rs 3,571.22 cr (as at 31.03.2026)
• Basic EPS (face value Rs 2/- per equity share): Rs 23.44 vs Rs 20.32 (Not Annualised)
• Diluted EPS (face value Rs 2/- per equity share): Rs 23.37 vs Rs 20.25 (Not Annualised)

According to the statement of unaudited consolidated financial results for the quarter and half year ended September 30, 2026 (Q2 FY27 column vs Q2 FY26 column), Caplin Point Laboratories’ consolidated revenue from operations increased to Rs 629.84 cr from Rs 534.04 cr a year earlier, while total income rose to Rs 663.13 cr from Rs 564.41 cr. Cost of materials consumed, purchase of traded goods and other expenses all moved up year-on-year, and depreciation & amortisation expense increased to Rs 23.49 cr from Rs 18.40 cr.

Profit before tax for the quarter stood at Rs 232.83 cr compared with Rs 201.00 cr in the corresponding quarter of the previous year. After total tax expenses of Rs 50.48 cr versus Rs 40.77 cr a year ago, net profit (PAT) came in at Rs 182.35 cr against Rs 160.23 cr. Basic EPS for the quarter was Rs 23.44 (Not Annualised), up from Rs 20.32 (Not Annualised) in Q2 FY26, on an unchanged equity share capital base of Rs 15.20 cr.

Get Caplin Point Laboratories Ltd's next results the minute they're filed

Results reach the exchange at all hours, most of them after the market closes. Pro puts the filing in your feed as it is published, with our read of the numbers. A free account sees it an hourback for a day.

  • We'll start you off following CAPLIPOINT.
  • 14 days free, no card. After that you keep a free account.

Get every filing that moves a stock

One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.

Cruxal publishes market coverage for information only. Nothing here is investment advice.

Caplin Point Q2 FY27 Results: Revenue Rs 629.84 cr | Cruxal